Novel Biomarkers – sRAGE
sRAGE
sRAGE is the soluble form of the RAGE receptor found in blood. Unlike membrane-bound RAGE, sRAGE lacks a signalling domain, meaning it does not trigger inflammation. Instead, it acts as a “decoy receptor”, binding harmful ligands and inhibiting pro-inflammatory RAGE signalling.
This anti-inflammatory potential makes sRAGE an important marker of immune balance and a candidate for identifying individuals at risk of developing chronic disease.
Other Applications
sRAGE demonstrates promising potential for broader clinical applications, including risk assessment, early diagnosis, and treatment monitoring in conditions such as obesity, diabetes, liver disease, cardiovascular disease, and chronic kidney disease.
Biochip Array Technology
Randox biochip technology enables precise measurement of sPD-1, providing valuable insights into immune regulation and disease progression.
The Evidence MultiSTAT
Meet the Evidence MultiSTAT
The Evidence MultiSTAT is an easy to use, small footprint analyser facilitating on-site simultaneous detection of multiple biomarkers.
Using chemiluminescence as a measurement principle, the Evidence MultiSTAT consistently delivers accurate results.
With minimal sample preparation required, this versatile benchtop analyser can achieve accurate, quantitative results in minutes.
Meet the Cartridge
The Evidence MultiSTAT cartridge contains the reagents required for the chemiluminescent reaction to take place incorporated into its wells.
The process from sample entry to results can be completed in 2 simple steps, with minimal risk of human error.
No other components are required.
References
Basta, G., Leonardis, D., Mallamaci, F., et al. (2010). Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney International, 77, 225–231.
Basta, G., Sironi, A. M., Lazzerini, G., et al. (2006). Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. The Journal of Clinical Endocrinology & Metabolism, 91, 4628–4634.
Devangelio, E., Santilli, F., Formoso, G., et al. (2007). Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radical Biology & Medicine, 43, 511–518.
Dozio, E., Briganti, S., Delnevo, A., et al. (2017). Relationship between soluble receptor for advanced glycation end products (sRAGE), body composition and fat distribution in healthy women. European Journal of Nutrition, 56, 2557–2564.
Erusalimsky, J. D. (2021). The use of the soluble receptor for advanced glycation-end products (sRAGE) as a potential biomarker of disease risk and adverse outcomes. Redox Biology, 42, 101958.
Falcone, C., Bozzini, S., Guasti, L., et al. (2013). Soluble RAGE plasma levels in patients with coronary artery disease and peripheral artery disease. The Scientific World Journal, 2013, 584504.
Falcone, C., Emanuele, E., D’Angelo, A., et al. (2005). Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arteriosclerosis, Thrombosis, and Vascular Biology, 25, 1032–1037.
Geroldi, D., Falcone, C., Minoretti, P., et al. (2006). High levels of soluble receptor for advanced glycation end products may be a marker of extreme longevity in humans. Journal of the American Geriatrics Society, 54, 1149–1150.
Huang, M., Que, Y., & Shen, X. (2015). Correlation of the plasma levels of soluble RAGE and endogenous secretory RAGE with oxidative stress in pre-diabetic patients. Journal of Diabetes and its Complications, 29, 422–426.
Hudson, B. I., Dong, C., Gardener, H., et al. (2014). Serum levels of soluble receptor for advanced glycation end-products and metabolic syndrome: the Northern Manhattan Study. Metabolism, 63, 1125–1130.
Issa, H. A., Elshaer, O. S., Awadallah, A. M., & El-Adl, T. (2012). Soluble receptor for advanced glycation end products: a new biomarker in diagnosis of diabetic nephropathy. Life Science Journal, 9, 1623–1629.
Ivancovsky-Wajcman, D., Zelber-Sagi, S., Fliss Isakov, N., et al. (2019). Serum soluble receptor for AGE (sRAGE) levels are associated with unhealthy lifestyle and nonalcoholic fatty liver disease. Clinical and Translational Gastroenterology, 10, e00034.
Jensen, L. J., Lindberg, S., Hoffmann, S., et al. (2015). Dynamic changes in sRAGE levels and relationship with cardiac function in STEMI patients. Clinical Biochemistry, 48, 297–301.
Kalousová, M., Hodková, M., Kazderová, M., et al. (2006). Soluble receptor for advanced glycation end products in patients with decreased renal function. American Journal of Kidney Diseases, 47, 406–411.
Kalousová, M., Jáchymová, M., Mestek, O., et al. (2007). Receptor for advanced glycation end products – soluble form and gene polymorphism in chronic haemodialysis patients. Nephrology Dialysis Transplantation, 22, 2020–2026.
Kanikowska, D., Kanikowska, A., Strojny, Z., et al. (2024). Assessment of EN-RAGE, sRAGE, and its isoforms: cRAGE, esRAGE in obese patients treated by moderate caloric restriction combined with physical activity conducted in hospital condition. Cytokine, 173, 156665.
Kierdorf, K., & Fritz, G. (2013). RAGE regulation and signaling in inflammation and beyond. Journal of Leukocyte Biology, 94, 55–68.
Koyama, H., Shoji, T., Yokoyama, H., et al. (2005). Plasma levels of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 25, 2587–2593.
Laudenslager, M., Lazo, M., Wang, D., et al. (2021). Association between the soluble receptor for advanced glycation end products (sRAGE) and NAFLD in participants in the Atherosclerosis Risk in Communities Study. Digestive and Liver Disease, 53, 873–878.
McNair, E. D., Wells, C. R., Qureshi, A. M., et al. (2009). Low levels of soluble receptor for advanced glycation end products in non-STE elevation myocardial infarction patients. The International Journal of Angiology, 18, 187–192.
McNair, E. D., Wells, C. R., Qureshi, A. M., et al. (2011). Inverse association between cardiac troponin-I and soluble receptor for advanced glycation end products in patients with non-ST-segment elevation myocardial infarction. The International Journal of Angiology, 20, 49–54.
Miranda, E. R., Somal, V. S., Mey, J. T., et al. (2017). Circulating soluble RAGE isoforms are attenuated in obese, impaired-glucose-tolerant individuals and are associated with the development of type 2 diabetes. American Journal of Physiology – Endocrinology and Metabolism, 313, E631–E640.
Nakamura, K., Yamagishi, S., Adachi, H., et al. (2007). Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes/Metabolism Research and Reviews, 23, 368–371.
Nakashima, A., Carrero, J. J., Qureshi, A. R., et al. (2010). Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. Clinical Journal of the American Society of Nephrology, 5, 2213–2219.
Norata, G. D., Garlaschelli, K., Grigore, L., et al. (2009). Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. Nutrition, Metabolism and Cardiovascular Diseases, 19, 129–134.
Palma-Duran, S. A., Kontogianni, M. D., Vlassopoulos, A., et al. (2018). Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease. Metabolism, 85, 120–127.
Park, H. J., Baek, J. Y., Shin, W. S., et al. (2011). Soluble receptor of advanced glycated end products is associated with plaque vulnerability in patients with acute myocardial infarction. Circulation Journal, 75, 1685–1690.
Prasad, K., Dhar, I., Zhou, Q., et al. (2016). AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease. Molecular and Cellular Biochemistry, 423, 105–114.
Rebholz, C. M., Astor, B. C., Grams, M. E., et al. (2015). Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities study. Nephrology Dialysis Transplantation, 30, 77–83.
Reyaz, A., Alam, S., Chandra, K., et al. (2020). Methylglyoxal and soluble RAGE in type 2 diabetes mellitus: association with oxidative stress. Journal of Diabetes and Metabolic Disorders, 19, 515–521.
Sabbatinelli, J., Castiglione, S., Macrì, F., et al. (2022). Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study. Cardiovascular Diabetology, 21, 95.
Selvin, E., Halushka, M. K., Rawlings, A. M., et al. (2013). sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes, 62, 2116–2121.
Steenbeke, M., Speeckaert, R., Desmedt, S., et al. (2022). The role of advanced glycation end products and its soluble receptor in kidney diseases. International Journal of Molecular Sciences, 23, 3439.
Tam, X. H., Shiu, S. W., Leng, L., et al. (2011). Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in type 2 diabetes. Clinical Science, 120, 81–89.
Tayyib, N. A., Ramaiah, P., Alshahrani, S. H., et al. (2023). Soluble receptor for advanced glycation end products (sRAGE) is associated with obesity rates: a systematic review and meta-analysis. BMC Endocrine Disorders, 23, 275.
Villegas-Rodríguez, M. E., Uribarri, J., Solorio-Meza, S. E., et al. (2016). The AGE-RAGE axis and its relationship to markers of cardiovascular disease in newly diagnosed diabetic patients. PLOS One, 11, e0159175.
Wong, F. N., Tan, J. A., Keng, T. C., et al. (2016). Association between plasma soluble RAGE and renal function is unaffected by medication usage and enzymatic antioxidants in chronic kidney disease with type 2 diabetes. Clinica Chimica Acta, 453, 56–61.
Yilmaz, Y., Ulukaya, E., Gul, O. O., et al. (2009). Decreased plasma levels of soluble receptor for advanced glycation end products (sRAGE) in patients with nonalcoholic fatty liver disease. Clinical Biochemistry, 42, 802–807.
Zakiyanov, O., Kalousová, M., Kříha, V., et al. (2011). Serum S100A12 (EN-RAGE) levels in patients with decreased renal function and subclinical chronic inflammatory disease. Kidney & Blood Pressure Research, 34, 457–464.
Zakiyanov, O., Kriha, V., Vachek, J., et al. (2013). Placental growth factor, pregnancy-associated plasma protein-A, sRAGE, and other biomarkers in acute kidney injury: a cross-sectional study. BMC Nephrology, 14, 245.
Zelber-Sagi, S., Salomone, F., Kolodkin-Gal, I., et al. (2017). Protective role of soluble receptor for advanced glycation end-products in patients with non-alcoholic fatty liver disease. Digestive and Liver Disease, 49, 523–529.